Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;19(7):561-568.
doi: 10.1080/14737140.2019.1631800. Epub 2019 Jun 25.

The role of combination chemo-immunotherapy in advanced non-small cell lung cancer

Danilo Rocco  1 , Luigi Della Gravara  2 , Ciro Battiloro  1 , Cesare Gridelli  3
Affiliations
Review

The role of combination chemo-immunotherapy in advanced non-small cell lung cancer

Danilo Rocco et al. Expert Rev Anticancer Ther. 2019 Jul.

Abstract

Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorable results- in order to increase the PFS and OS rates of these patients. Areas covered: Therefore, this paper aims to discuss the most promising trials investigating chemo-immunotherapy combinations and their present and future impact on advanced NSCLC treatment paradigms. Expert opinion: First line chemo-immunotherapy combinations are starting to and will certainly revolutionize the current paradigm of metastatic non small cell lung cancer treatment due to their superior performances - both in terms of PFS and OS - when compared to the actual standard of care platinum based chemotherapy. However, these associations are not devoid of problems, in fact, combining immunotherapy with chemotherapy obviously leads to enhanced treatment-related toxicities and to higher discontinuation rates; therefore these treatments should be administered carefully.

Keywords: Advanced NSCLC; atezolizumab; chemo-immunotherapy; chemo-immunotherapy combinations; chemotherapy; combination therapy; immunotherapy; nivolumab; pembrolizumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources